Home Tools
Log in
Cart

VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated

Catalog No. TMPY-06620
Synonyms: PCL, VEGFR-3, LMPH1A, fms related tyrosine kinase 4, FLT-41, FLT41, VEGFR3, FLT-4, VEGF Receptor 3

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated
Pack Size Availability Price/USD Quantity
20 μg 5 days $ 600.00
100 μg 5 days $ 1,390.00
Bulk Inquiry
Get quote
Contact us for more batch information
Biological Description
Technical Params
Product Properties
References and Literature
Description Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
Species Human
Expression System HEK293
Tag His,AVI
Accession Number NP_002011.2
Synonyms PCL, VEGFR-3, LMPH1A, fms related tyrosine kinase 4, FLT-41, FLT41, VEGFR3, FLT-4, VEGF Receptor 3
Construction A DNA sequence encoding the human VEGFR3/FLT4 (NP_002011.2) (Met1-Ile776) was expressed with a C-terminal Avi tag followed by a His tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed.
Protein Purity > 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC.
Molecular Weight Approxiamtely 87.80 kDa
Endotoxin < 1.0 EU per μg protein as determined by the LAL method.
Formulation Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Reconstitution A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
Stability & Storage

Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Shipping

In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Research Background Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

References and Literature

Calculator

Reconstitution Calculator
Recombinant Proteins Dilute Calculator
Specific Activity Calculator
=
÷
X
=
X
(Unit/mg)
= 106 ÷
ng/mL

bottom

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords

VEGFR3/FLT4 Protein, Human, Recombinant (His & Avi), Biotinylated PCL VEGFR-3 LMPH1A fms related tyrosine kinase 4 FLT-41 VEGFR 3 FLT 41 FLT41 VEGFR3 FLT-4 FLT4 VEGF Receptor 3 FLT 4 recombinant recombinant-proteins proteins protein

 

TargetMol